What is povorcitinib, and why is it being studied?
Povorcitinib is an investigational oral medicine developed by Incyte that selectively inhibits JAK1. That immune-signaling effect supplies a rationale for vitiligo research, but it does not establish clinical benefit, approval, or individual suitability. Evidence This statement has a dated source and is waiting for a clinician's sign-off. Pending clinical review
Why this matters
The peer-reviewed phase 2 study provides clinical evidence in extensive nonsegmental vitiligo, not just a laboratory theory.
Questions for a trial investigator or systemic-treatment specialist
- What is the goal for my vitiligo?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Which evidence is clinical rather than mechanistic?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Is povorcitinib approved and available for vitiligo?
The reviewed STOP-V1 and STOP-V2 registries and Incyte update describe povorcitinib as a vitiligo research candidate, and Incyte says regulatory filings are planned for 2027. Those sources do not establish current authorization status in every jurisdiction. A successful trial or future filing plan is not a regulator decision, an approved label, or commercial availability for vitiligo. Evidence Evidence Evidence This statement has a dated source and is waiting for a clinician's sign-off. Pending clinical review
Why this matters
The current records describe a research program. Trial completion, a positive endpoint, and a future filing are milestones - not approval.
Questions for a trial investigator or systemic-treatment specialist
- Is access limited to a trial?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Has any regulator issued a vitiligo decision since this review?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Which current regulator record supports that answer?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Who was studied, and what did the trials show?
A peer-reviewed randomized phase 2 study enrolled 171 adults with extensive nonsegmental vitiligo. At week 24, the mean total-body score improved by 15.7% to 19.1% across the studied povorcitinib groups while the placebo group worsened by 2.3%; the study reported limited demographic diversity. A later descriptive post hoc analysis followed 103 people who received povorcitinib throughout the study. It reported week-52 VASI50 response proportions from 25.8% for feet to 57.3% for head and neck outside the face. It had no placebo comparison at week 52 and cannot predict an individual site. The registries list 467 participants in STOP-V1 and 450 in STOP-V2. Incyte later said that at week 52, 18.9% reached F-VASI75 (at least 75% improvement from baseline in the facial score). That was versus 6.8% with placebo in STOP-V1, and 18.9% versus 3.1% in STOP-V2. Those phase 3 percentages are sponsor-reported topline results, not posted registry results or peer-reviewed findings. Evidence Evidence Evidence Evidence Evidence This statement has a dated source and is waiting for a clinician's sign-off. Pending clinical review
Why this matters
The phase 2 paper provides an absolute mean total-body change for 171 adults. The phase 3 sponsor update provides an absolute facial response proportion for each study and comparator.
Questions for a trial investigator or systemic-treatment specialist
- Do I resemble the extensive adult phase 2 population?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Where are the full phase 3 result and safety tables?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What outcome would be meaningful for my body sites?Saving keeps this on your device and needs JavaScript, which is off in this browser.
What is known, and not known, about safety?
The phase 2 publication reported a similar incidence of grade 3 or higher treatment-emergent adverse events across study groups, and no new safety signal. The phase 3 registries excluded people with several infection, cancer, cardiovascular, clotting, pregnancy, laboratory, and prior-treatment risks. The reviewed sources do not include an approved povorcitinib vitiligo product label. So they do not supply a complete labeled contraindication, warning, interaction, monitoring, pregnancy, or long-term safety profile. Safety language from another JAK medicine cannot be transferred as if it were povorcitinib evidence. Evidence Evidence Evidence Evidence This statement has a dated source and is waiting for a clinician's sign-off. Pending clinical review
Why this matters
The study publications and protocols can report observed events and describe who was excluded. They do not replace the contraindications, warnings, interactions, monitoring, and population sections of an approved product label.
Questions for a trial investigator or systemic-treatment specialist
- Which safety findings were observed, and which risks were excluded by eligibility rules?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What tests, monitoring, pregnancy, infection, and interaction rules does this protocol require?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What remains unknown without an approved product label?Saving keeps this on your device and needs JavaScript, which is off in this browser.
What does research access involve?
The reviewed vitiligo access path is research, not routine commercial prescribing. Trial sites and eligibility determine research access. Future approval, market supply, specialist workflow, payer coverage, personal cost, and post-trial access are not established by the reviewed sources. Evidence Evidence Evidence This statement has a dated source and is waiting for a clinician's sign-off. Pending clinical review
Why this matters
A trial conversation should cover randomization, placebo, visits, tests, travel, reporting, leaving the study, usual care, injury, costs, privacy, results, and access after participation.
Questions for a trial investigator or systemic-treatment specialist
- Which visits, tests, travel, costs, and privacy rules apply?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What care and information do I receive if I leave?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What happens to treatment access after the study?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Has povorcitinib been shown to work better with narrowband UVB?
The reviewed phase 2 publication and STOP-V1 and STOP-V2 registries studied povorcitinib against placebo rather than a narrowband-UVB add-on strategy. SteadySkin did not verify a controlled vitiligo combination result, so separate evidence for phototherapy or another medicine cannot be joined into a povorcitinib combination claim. Evidence Evidence Evidence This statement has a dated source and is waiting for a clinician's sign-off. Pending clinical review
Why this matters
The reviewed pivotal program tests povorcitinib against placebo. That can answer a medicine-versus-placebo question, not a medicine-plus-light question.
Questions for a trial investigator or systemic-treatment specialist
- Has this exact combination been studied in a controlled vitiligo trial?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Which component is expected to add what?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What new harm, monitoring, and burden would the combination add?Saving keeps this on your device and needs JavaScript, which is off in this browser.
What remains unknown, and how should I use participant stories?
Several things remain unresolved: full peer-reviewed phase 3 results, complete safety tables, durability, and phase 3 subgroup findings. So do reliable individual-body-site predictions beyond the small descriptive phase 2 follow-up, regulatory decisions, and commercial access. A trial participant’s story can describe visits, uncertainty, and lived burden, but it cannot establish a typical outcome or replace the protocol and investigator discussion. Evidence Evidence Evidence Evidence Evidence This statement has a dated source and is waiting for a clinician's sign-off. Pending clinical review
Why this matters
Participant accounts can help name visit burden, uncertainty, side-effect conversations, randomization, hopes, disappointment, and post-trial access questions.
Questions for a trial investigator or systemic-treatment specialist
- Which phase 3 facts are still missing?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What would make me pause, decline, leave, or revisit this path?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Which approved, support, or no-treatment paths remain available?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Questions that can change the next decision
- For the trial teamWhich protocol, eligibility rules, randomization, stopping rules, and post-trial access apply?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- For the trial teamWhich safety facts are observed, suspected, excluded by the protocol, or still unknown?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- For your specialistHow does a research path compare with approved, off-label, support, or no-treatment choices for my goal?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence snapshot
The peer-reviewed phase 2 study supplies bounded adult group outcomes; phase 3 percentages remain a manufacturer topline without posted registry result tables.
- Phase 2
- Randomized study of 171 adults with extensive nonsegmental vitiligo.
- Phase 3
- STOP-V1 lists 467 participants and STOP-V2 lists 450. Both met a sponsor-reported facial endpoint; full results remain unpublished.
- Status
- Investigational; future filing plans are not regulator decisions.
- Safety
- No approved povorcitinib product label supplies a complete vitiligo safety and monitoring profile.
Applicability check
Who was studied?
These fields show what the cited evidence reports about the people and body sites behind outcome or safety claims. “Not reported” means the reviewed source omitted the field; “Pending exact source review” means SteadySkin has not made that determination yet.
A peer-reviewed randomized phase 2 study enrolled 171 adults with extensive nonsegmental vitiligo. At week 24, the mean total-body score improved by 15.7% to 19.1% across the studied povorcitinib groups while the placebo group worsened by 2.3%; the study reported limited demographic diversity. A later descriptive post hoc analysis followed 103 people who received povorcitinib throughout the study. It reported week-52 VASI50 response proportions from 25.8% for feet to 57.3% for head and neck outside the face. It had no placebo comparison at week 52 and cannot predict an individual site. The registries list 467 participants in STOP-V1 and 450 in STOP-V2. Incyte later said that at week 52, 18.9% reached F-VASI75 (at least 75% improvement from baseline in the facial score). That was versus 6.8% with placebo in STOP-V1, and 18.9% versus 3.1% in STOP-V2. Those phase 3 percentages are sponsor-reported topline results, not posted registry results or peer-reviewed findings.
- Age range
- Adults.
- Condition subtype
- Nonsegmental vitiligo.
- Severity or extent
- Phase 2 studied extensive disease. The phase 3 registries required minimum total-body and facial involvement using prespecified body-surface and VASI thresholds.
- Sample size
- Phase 2 randomized 171 adults. The phase 3 registries list 467 participants in STOP-V1 and 450 in STOP-V2.
- Geography and care setting
- A multicenter study conducted in Canada and the United States.
- Skin tone or phototype
- The descriptive extension analysis reported Fitzpatrick type subgroups.
- Race
- The descriptive extension analysis reported White and non-White subgroups.
- Ethnicity
- The phase 2 publication reported 32 of 171 participants (18.7%) as Hispanic.
- Body sites
- Facial and total-body scores were reported. A descriptive post hoc analysis of 103 extension-evaluable participants reported week-52 VASI50 response proportions from 25.8% for feet to 57.3% for head and neck outside the face. It was pooled, post hoc and lacked a week-52 placebo comparator.
What that means for this page: The peer-reviewed numeric result applies most directly to adults with extensive nonsegmental vitiligo resembling the phase 2 population. The separate STOP-V1 and STOP-V2 percentages are sponsor toplines for phase 3 adults meeting registry-defined minimum facial and total-body involvement. Phase 3 demographic subgroup tables are not public. Limited phase 2 demographic diversity and descriptive post hoc subgroup and body-region analyses restrict generalization; group results do not predict an individual or body-site response.
The phase 2 publication reported a similar incidence of grade 3 or higher treatment-emergent adverse events across study groups, and no new safety signal. The phase 3 registries excluded people with several infection, cancer, cardiovascular, clotting, pregnancy, laboratory, and prior-treatment risks. The reviewed sources do not include an approved povorcitinib vitiligo product label. So they do not supply a complete labeled contraindication, warning, interaction, monitoring, pregnancy, or long-term safety profile. Safety language from another JAK medicine cannot be transferred as if it were povorcitinib evidence.
- Age range
- Adults.
- Condition subtype
- Nonsegmental vitiligo.
- Severity or extent
- Extensive disease in phase 2.
- Sample size
- 168 treated adults in the phase 2 safety population.
- Geography and care setting
- A multicenter study conducted in Canada and the United States.
- Skin tone or phototype
- The phase 2 publication reported baseline Fitzpatrick skin-type categories.
- Race
- The phase 2 publication reported baseline race categories and noted limited demographic diversity.
- Ethnicity
- The phase 2 randomized population included 32 of 171 participants (18.7%) identified as Hispanic.
- Body sites
- Not reported
What that means for this page: Shorter-term study reporting and phase 3 eligibility rules do not supply a complete commercial-product safety profile, long-term risk estimate, pediatric evidence, or personal risk calculation.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- Journal of the American Academy of Dermatology (Pandya AG, et al.)Randomized trial · Clinical research, tier 2Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: Incyte sponsored the study; several authors were Incyte employees or shareholders, and other authors disclosed company relationships.
What this source supports
Supports the randomized phase 2 design, 171 adults with extensive nonsegmental vitiligo, group-level total-body outcome, continued improvement in the extension, reported study safety and the explicit limitation of limited demographic diversity.
What it does not support
The sponsor-linked trial does not establish approval, direct superiority over another treatment, every body-site outcome, a full commercial-product safety profile, long-term safety or an individual result.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Advances in Therapy (Passeron T, et al.)Observational study · Supporting research, tier 3Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: Incyte sponsored the underlying study; several authors were Incyte employees or shareholders and other authors disclosed company relationships.
What this source supports
Supports a descriptive post hoc analysis of 103 extension-evaluable adults who received povorcitinib throughout the phase 2 study, including subgroup reporting and week-52 VASI50 response proportions ranging from 25.8% for feet to 57.3% for head and neck outside the face.
What it does not support
The small pooled extension analysis was post hoc, descriptive and lacked a placebo comparator at week 52. It does not establish a reliable individual body-site prediction, phase 3 subgroup results, comparative superiority, approval, long-term safety or a personal treatment plan.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- ClinicalTrials.gov, U.S. National Library of MedicineTrial registry · Supporting research, tier 3Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: ClinicalTrials.gov hosts the record, while Incyte sponsors the study and supplies the registered information.
What this source supports
Supports the adult randomized phase 3 design, nonsegmental-vitiligo eligibility, 467-person enrollment record, study status, registered facial outcome and absence of posted result tables when reviewed.
What it does not support
Registration is not peer review, a regulatory decision, a published benefit-risk conclusion or a personal treatment plan.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- ClinicalTrials.gov, U.S. National Library of MedicineTrial registry · Supporting research, tier 3Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: ClinicalTrials.gov hosts the record, while Incyte sponsors the study and supplies the registered information.
What this source supports
Supports the adult randomized phase 3 design, nonsegmental-vitiligo eligibility, 450-person enrollment record, study status, registered facial outcome and absence of posted result tables when reviewed.
What it does not support
Registration is not peer review, a regulatory decision, a published benefit-risk conclusion or a personal treatment plan.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Incyte CorporationManufacturer document · Manufacturer, tier 4Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: Incyte develops povorcitinib, sponsored the studies, analyzed the results and issued the topline update before full peer-reviewed results were available.
What this source supports
Supports only Incyte’s report that STOP-V1 and STOP-V2 met the facial endpoint, the stated absolute response percentages, selected topline safety language and planned future vitiligo regulatory filings.
What it does not support
The update is not peer-reviewed publication, a regulator decision, proof of availability, direct comparison with another treatment, a complete safety profile or an individual prediction.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.